This randomized controlled trial aims to investigate the effects of a 24-week home-based progressive resistance exercise program combined with tirzepatide treatment on skeletal muscle mass, muscle quality, and functional capacity in overweight and obese individuals. A total of 108 participants initiating tirzepatide therapy will be randomized to either exercise plus pharmacotherapy or pharmacotherapy alone. The primary outcome is change in thigh muscle thickness and echo intensity assessed by ultrasonography.
initiation of tirzepatide-based pharmacological treatment as prescribed by an endocrinology and metabolism specialist,
body mass index (BMI) ≥27 kg/m² and the presence of a comorbidity condition or BMI≥30 kg/m²
age between 18 and 65 years
diagnosis of type 1 or type 2 diabetes mellitus
presence of cerebrovascular, hematological, pulmonary, rheumatological, or neurological disorders
current participation in a structured diet or exercise program
use of weight-loss medications within the past 12 months